Dashboard
Manage Tickers

OCGN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

forecasting-the-future-4-analyst-projections-for-ocugen
Forecasting The Future: 4 Analyst Projecti...
09/19/2025 12:01:52

on-sept-16-carisma-terminates-merger-agreement-with-ocugen
On Sept 16, Carisma Terminates Merger Agre...
09/18/2025 15:14:41

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/17/2025 21:06:24

ocugen-shares-are-trading-higher-monday-whats-going-on
Ocugen Shares Are Trading Higher Monday: W...
09/15/2025 20:29:16

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the...

ocugen-strikes-75m-licensing-deal-giving-kwangdong-exclusive-korean-rights-to-gene-therapy-for-blindness
Ocugen Strikes $7.5M Licensing Deal Giving...
09/15/2025 10:10:53

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for...

Core News & Articles
Carisma Therapeutics To Receive $5M Invest...
08/29/2025 20:26:43

 

the-committee-for-medicinal-products-for-human-use-of-the-european-medicines-agency-reviewed-the-study-design-endpoints-and-planned-statistical-analysis-of-ocugens-ongoing-ocu410st-phase-23-gardian3-trial-for-stargardt-disease-and-provided-acceptability-of-a-single-us-based-trial-for-submission-of-a-marketing-authorization-application
The Committee For Medicinal Products For H...
08/13/2025 10:29:45

With enrollment scheduled to be complete in the first quarter of 2026 the Company remains on track for a BLA filing in the firs...

ocugen-announces-20m-direct-offering-of-20m-shares-and-20m-warrants-at-a-combined-price-of-100
Ocugen Announces $20M Direct Offering Of 2...
08/08/2025 21:07:37

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases,...

demystifying-ocugen-insights-from-5-analyst-reviews
Demystifying Ocugen: Insights From 5 Analy...
08/04/2025 13:03:05

chardan-capital-maintains-buy-on-ocugen-maintains-7-price-target
Chardan Capital Maintains Buy on Ocugen, M...
08/04/2025 11:16:28

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.

ocugen-q2-eps-005-beats-006-estimate-sales-1373m-beat-350000k-estimate
Ocugen Q2 EPS $(0.05) Beats $(0.06) Estima...
08/01/2025 13:54:09

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 19....

Core News & Articles
Earnings Scheduled For August 1, 2025
08/01/2025 08:32:17

a-peek-at-ocugens-future-earnings
A Peek at Ocugen's Future Earnings
07/31/2025 18:01:19

us-court-granted-ocugens-motion-to-dismiss-securities-class-action-lawsuit
U.S. Court Granted Ocugen's Motion To Dism...
07/30/2025 21:13:44

-SEC Filing

ocugen-reports-first-patient-dosed-in-phase-23-gardian3-clinical-trial-for-ocu410st-modifier-gene-therapy-candidate-being-developed-for-all-stargardt-disease
Ocugen Reports First Patient Dosed In Phas...
07/18/2025 11:03:45

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases,...

chardan-capital-maintains-buy-on-ocugen-maintains-7-price-target
Chardan Capital Maintains Buy on Ocugen, M...
06/24/2025 12:03:08

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.

hc-wainwright--co-reiterates-buy-on-ocugen-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Ocug...
06/24/2025 10:54:28

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price tar...

ocugen-ocgn-shares-slide-following-merger-agreement-whats-going-on
Ocugen (OCGN) Shares Slide Following Merge...
06/23/2025 18:26:09

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidia...

Core News & Articles
Carisma Therapeutics And Ocugen Subsidiary...
06/23/2025 11:42:46

ocugen-ocgn-stock-soars-on-fda-clearance-for-pivotal-stargardt-disease-trial
Ocugen (OCGN) Stock Soars On FDA Clearance...
06/16/2025 14:58:45

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help pat...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION